0718 GMT - Novartis's trial results for its ianalumab drug candidate in autoimmune disorder Sjoegren's disease suggests the company's next pipeline in a pill--or a drug marketed for multiple indications--could be under way, Vontobel's Stefan Schneider says in a research note. The Swiss pharmaceutical company said it is testing the drug in other diseases. Ianalumab worked in two late-stage trials and this could pave the way for a systematic treatment for a disease for which there are only limited symptomatic treatments available at the moment, the analyst says. This could increase the diagnosis rate, as the scientific literature estimates 50% of patients are undiagnosed, the analyst says. Vontobel estimates peak sales for the drug at $1 billion. Novartis shares rise 2.3%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
August 11, 2025 03:18 ET (07:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。